Unknown

Dataset Information

0

Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation.


ABSTRACT: The emergence of resistance to imatinib mediated by mutations in the BCR-ABL has become a major challenge in the treatment of chronic myeloid leukemia (CML). Alternative therapeutic strategies to override imatinib-resistant CML are urgently needed. In this study, we investigated the effect of AKI603, a novel small molecule inhibitor of Aurora kinase A (AurA) to overcome resistance mediated by BCR-ABL-T315I mutation. Our results showed that AKI603 exhibited strong anti-proliferative activity in leukemic cells. AKI603 inhibited cell proliferation and colony formation capacities in imatinib-resistant CML cells by inducing cell cycle arrest with polyploidy accumulation. Surprisingly, inhibition of AurA by AKI603 induced leukemia cell senescence in both BCR-ABL wild type and T315I mutation cells. Furthermore, the induction of senescence was associated with enhancing reactive oxygen species (ROS) level. Moreover, the anti-tumor effect of AKI603 was proved in the BALB/c nude mice KBM5-T315I xenograft model. Taken together, our data demonstrate that the small molecule AurA inhibitor AKI603 may be used to overcome drug resistance induced by BCR-ABL-T315I mutation in CML.

SUBMITTER: Wang LX 

PROVIDER: S-EPMC5099696 | BioStudies | 2016-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC2893099 | BioStudies
2014-01-01 | S-EPMC3938960 | BioStudies
2015-01-01 | S-EPMC4359310 | BioStudies
2009-01-01 | S-EPMC2804470 | BioStudies
2010-01-01 | S-EPMC3066561 | BioStudies
2016-01-01 | S-EPMC4916441 | BioStudies
1000-01-01 | S-EPMC5352360 | BioStudies
1000-01-01 | S-EPMC5833368 | BioStudies
2015-01-01 | S-EPMC4581365 | BioStudies
2017-01-01 | S-EPMC5430391 | BioStudies